The Third
Dimension
of Human Health

Microcurrent Wound Healing — ATP +300–500%, Collagen & VEGF Upregulation

Microcurrent dressing accelerates wound healing via increased ATP synthesis, collagen production, angiogenesis stimulation. Wounds healed up to 3× faster.

Microcurrent Therapy — Tissue Repair, Neuropathy, Musculoskeletal & Neurological Benefits

Comprehensive review of microcurrent clinical evidence across tissue repair, nerve health, musculoskeletal, and neurological conditions.

Sperm Motility Enhanced 30–40% by Nano-Ampere Electrical Stimulation

Electrical stimulation in the nano-Ampere range enhanced human sperm motility via tyrosine phosphorylation and mitochondrial ATP activation.

Twice-Daily Electrical Stimulation Improves Cognitive Function in Alzheimer's — Phase II RCT

tDCS over 6 weeks significantly improved word recall and recognition in Alzheimer's patients. Cortical plasticity restored by bioelectric stimulation.

LLLT for Skin — Collagen, Psoriasis, Vitiligo, UV Damage, Wrinkles. 90%+ Patients Improved.

Red/NIR LEDs stimulate fibroblast collagen synthesis, reduce MMP-1 collagenase, and support a wide range of dermatological conditions.

LLLT for Psoriasis — 60–100% Clearance Rate, No Side Effects

830nm + 633nm LED combination treatment achieved 60–100% clearance in recalcitrant psoriasis patients — validated clinical review.

Frequency-Specific Microcurrent — Neuropathic Pain, Cytokine Reduction, Nerve Repair

FSM reduced IL-1, IL-6, TNF-α, Substance P and elevated endorphins. Dissolved fibrosis and promoted nerve tissue health.

Hyperthermia as Cancer Adjuvant — 51% vs 27% 3-Year Survival. 15+ Positive Phase III Trials.

Hyperthermia (40–43°C) as cancer adjuvant — immune activation, drug absorption enhancement, and tumour microenvironment modulation.

Electrical Pulse Stimulation Enhances Glucose & Fatty Acid Oxidation in Muscle Cells

Intermittent EPS enhanced complete glucose and fatty acid oxidation — supporting metabolic health and energy expenditure at the cellular level.

Bioelectric Medicine — Microcurrent Stimulation at the Cellular Level: A Comprehensive Review

Microcurrent at sub-sensory levels mimics the body's natural electrical activity, promoting ATP synthesis, protein synthesis, and cellular regeneration. Validates the core science behind VCF adjuvant therapy.

Portable Microcurrent Device: Real-World Study — Back Pain, Fibromyalgia, Migraine & Depression

Statistically significant SF-36 quality-of-life improvements across all five indications. Only 4 minor adverse events in the entire trial — confirming safety and efficacy of portable microcurrent devices.

Microcurrent Applied to the Heart — Improved Cardiac Function in Class II/III Heart Failure

First-in-human study: chronic microcurrent application improved myocardial performance in ambulatory heart failure patients. Safe, feasible, and showed measurable cardiac improvement.

Microcurrent Therapy as a Non-Pharmacological Protocol Against Alzheimer's Disease

Microcurrent therapy reduced neuroinflammation and ameliorated memory loss in Alzheimer's model — promising as a non-pharmacological adjuvant for cognitive decline.

TENS Reduces HbA1c in Type 2 Diabetes — 160-Patient Randomized Controlled Trial

Transcutaneous electrical nerve stimulation over 20 weeks significantly decreased HbA1c in oral antidiabetic drug-treated patients. Validates electrical stimulation as an adjuvant in glycaemic management.

Neuromuscular Electrical Stimulation Improves Glycaemic Control — Systematic Review & Meta-Analysis

Meta-analysis of 35 studies confirms NMES lowers fasting blood glucose (SMD: 0.48, p=0.002) in Type 2 diabetes, obesity, and spinal cord injury patients. Significant glycaemic adjuvant effect.

PEMF Therapy Reduces Blood Pressure & Improves Vascular Function in Hypertensive Patients

12 weeks of PEMF therapy significantly reduced peripheral blood pressure and improved nitric oxide levels in 30 hypertensive individuals — supporting adjuvant cardiovascular applications.

PEMF Therapy Improves Cardiac Recovery After Myocardial Infarction

Extracorporeal PEMF accelerated cardiac regeneration post-MI in animal models, reducing infarct size and improving ejection fraction. Supports cardiac adjuvant applications of electromagnetic therapy.

Music Therapy Reduces Chronic Pain, Depression & Anxiety — Systematic Review of RCTs

Meta-analysis of 9 RCTs (787 patients) confirms music therapy significantly reduces chronic pain and depression. Supports eMedica's patent-claimed music/frequency therapy modality (Claim 14 — HDMI/USB audio).

LLLT Accelerates Wound Healing & Pain Relief — Systematic Review & Meta-Analysis

Non-thermogenic low-level laser light significantly promotes tissue healing and alleviates pain in skin wounds — meta-analysis confirming LLLT's role as a non-invasive adjuvant healing modality.

Microcurrent Stimulation Enhances Peripheral Nerve Regeneration — 100μA Optimal Protocol

Continuous microcurrent nerve stimulation (cMENS) at 100μA activated Schwann cells and improved microenvironment for long-distance nerve defect repair. Directly relevant to eMedica's neuropathy adjuvant protocols.

LLLT for Inflammatory, Musculoskeletal & Autoimmune Disease — A Clinical Review

LLLT is non-invasive, has minimal side effects, is relatively inexpensive, and can be patient-directed at home. Validated as adjuvant for inflammatory and autoimmune conditions with no adverse effects.

The “Electricidal Effect” — Low-Intensity Electric Current Destroys Drug-Resistant Bacterial Biofilms

Prolonged exposure to 20–200 microampere direct current significantly reduced Staphylococcus and Pseudomonas biofilms — including antibiotic-resistant strains. Validates bioelectric therapy against chronic infections.

Bioelectric Effect & Bacterial Biofilms — Electric Current Enhances Antibiotic Efficacy 500–5,000×

Biofilm bacteria are resistant to antibiotics at levels 500–5,000× higher than needed to kill free bacteria. Electric current enhances antibiotic penetration into biofilm by several orders of magnitude — a breakthrough in infection management.

Bacterial Biofilm Destroyed by Electric Current via Reactive Oxygen Species (ROS)

Direct current kills biofilm bacteria through ROS generation — the same mechanism by which eMedica’s electron infusion creates a hostile environment for pathogens at the cellular level. Confirmed by confocal microscopy and flow cytometry.

Electromagnetic Energy (Microwave) Inactivates HIV-1 and Hepatitis C Virus

Microwave electromagnetic energy successfully inactivated both HIV-1 and HCV in vitro. Demonstrates that electromagnetic fields are capable of disrupting viral integrity — supporting the antiviral potential of frequency-based bioelectronic therapy.

Blue LED Photobiomodulation Inhibits SARS-CoV-2 Replication in Vero Cells

LED photobiomodulation at blue wavelengths (450–470 nm) significantly inhibited SARS-CoV-2 viral replication in vitro. Supports the antiviral capacity of eMedica’s LED/LLLT modality (Patent Claims 6, 11).

Photobiomodulation as Adjuvant Against COVID-19 — Reduces Cytokine Storm, Lung Inflammation

LLLT/PBM reduces TNF-α, IL-1β, IL-6, ROS and lung oedema, and increases red blood cell oxygenation. Systematic review confirms photobiomodulation as a viable adjuvant in viral respiratory infections.

Tumour Treating Fields (TTFields) Improve Glioblastoma Survival — Phase III RCT in JAMA

Alternating electric fields (200 kHz) significantly improved progression-free and overall survival in glioblastoma patients. TTFields are now FDA-approved for brain cancer — the landmark proof that electric fields can suppress cancer cell division in humans.

TTFields Meta-Analysis: Electric Field Therapy Reduces Cancer Death Risk by 37% (HR 0.63)

Meta-analysis of 7 studies (1,430 patients): TTFields + standard care vs standard care alone showed hazard ratio 0.63 (p<0.001) — 37% reduction in death risk. Median survival 22.6 months vs 17.4 months. Real-world validation.

Alternating Electric Fields Arrest Cancer Cell Division in Animal & Human Brain Tumours

Landmark PNAS study: low-intensity alternating electric fields at specific frequencies selectively disrupt mitosis in cancer cells without harming normal tissue. Foundational proof that frequency-targeted electrical therapy can arrest tumour growth.

Electrical Stimulation Generates Tumour-Suppressing Proteins — Inhibits Breast Cancer & Bone Metastasis

Electrically stimulated cells produce conditioned medium rich in tumour-suppressing proteins (including histone H4) that inhibit cancer cell migration, 3D spheroid growth, and bone metastasis. Direct evidence that electrical stimulation activates the body’s own anti-cancer mechanisms.

Photobiomodulation Modulates Immune System — Activates Macrophages, T-Cells & Dendritic Cells

Comprehensive review confirms LLLT/PBM activates macrophages, T cells, and dendritic cells through mitochondrial and ROS pathways — enhancing immune response against both pathogens and tumours. Relevant to eMedica’s LED/LLLT claims (Patent Claim 6).

Bioelectromagnetism & Modulated Electro-Hyperthermia — Targeted Non-Invasive Cancer Adjuvant

Modulated electromagnetic hyperthermia (mEHT) selectively destroys cancer cells through bioelectromagnetic resonance. Non-invasive, targeted, and demonstrated to complement traditional cancer therapies — directly aligned with eMedica’s thermal pad and frequency modalities.

Bioelectric Dysregulation in Cancer — Membrane Potential as a Driver of Cancer Initiation & Progression

Cancer is fundamentally a disease of bioelectric dysregulation. Disrupted cellular membrane potential (Vmem) drives uncontrolled cell division, invasion, and metastasis. Restoring Vmem is a validated target for arresting cancer progression — directly aligned with eMedica’s core science.

Membrane Potential & Cancer Progression — Cancer Cells Have Depolarised Voltage Vs. Normal Cells

Normal cells maintain −70 mV membrane potential. Cancer cells are depolarised (closer to 0 mV), enabling rapid proliferation. Restoring membrane potential is a valid and validated anti-cancer strategy — the foundation of eMedica’s approach.

Molecular Bioelectricity — Endogenous Voltage Potentials Control Cell Behaviour, Regeneration & Pattern Formation

Prof. Michael Levin (Harvard/Tufts) demonstrates that bioelectric patterns regulate tissue repair, organ patterning, stem cell behaviour, and cancer reversal. Cracking the “bioelectric code” is the basis of next-generation regenerative medicine.

Membrane Potential Declines with Age — Restoring It Reverses Ageing-Related Disease

The membrane hypothesis of ageing: declining membrane potential with age disrupts ion channel activity, impairs cellular energy metabolism, and causes senescence. Restoring membrane potential — as eMedica does via VCF — is a validated anti-ageing intervention.

Non-Invasive Electrical Neuromodulation for COPD Breathlessness — RCT Protocol

Transcutaneous vagus nerve stimulation (tVNS) and TENS are being trialled for COPD-related dyspnoea. Validates electrical stimulation as adjuvant support for chronic respiratory conditions — a new frontier directly relevant to eMedica’s VCF adjuvant therapy.

Hijacking Bioelectricity in Cancer — All Cells Are Electrically Active; Bioelectric Circuitry Governs Cancer

Landmark review: every cell possesses bioelectric circuitry generating a resting membrane potential. Cancer arises from malfunctions in this circuitry. Bioelectronic medicine offers treatments that manipulate bioelectrical properties — sensing, controlling, and eliciting morphological changes in cancer cells.

Non-Invasive Transcranial Electrical Stimulation for Parkinson’s Disease — Emerging Adjuvant Modality

Transcranial electrical stimulation (tES) modulates brain activity and reduces motor symptoms in Parkinson’s disease. Novel optimised protocols show improved therapeutic efficacy across tremor, rigidity, and cognitive function — supporting eMedica’s neurological applications.

Peripheral Electrical Stimulation — Safe, Non-Invasive Tremor Reduction in Parkinson’s & Essential Tremor

Non-invasive peripheral nerve electrical stimulation reduces pathological tremor in Parkinson’s disease and essential tremor patients. One specific PES therapy is FDA-cleared for home use. Confirms eMedica’s VCF modality as adjuvant support for neurological motor conditions.

Electrical Muscle Stimulation Improves Strength, Function & Quality of Life in Chronic Kidney Disease

Neuromuscular electrical stimulation (NMES) in haemodialysis patients significantly improved muscle strength, functional capacity, and postural balance. Offers a novel therapeutic adjuvant for kidney disease patients — validated in RCT.

Bioelectronic Approaches Protect the Kidney — Vagus Nerve Stimulation & Electrical Modulation Prevent Acute Kidney Injury

Electrical vagus nerve stimulation, ultrasound, and bioelectric neuromodulation activate the cholinergic anti-inflammatory pathway, providing renal protection in acute kidney injury models. Validates the systemic anti-inflammatory reach of bioelectronic adjuvant therapy.

LLLT for Male & Female Pattern Hair Loss — 10 RCTs, Significant Hair Density Increase, FDA-Cleared

Review of 10 RCTs confirms LLLT (600–1,100 nm) produces statistically significant increases in hair density and diameter in androgenetic alopecia. All sham-controlled studies showed significant benefit. FDA-cleared low-level laser devices now exist for home use.

Wearable Transcranial Electrical Stimulation at 0.75 Hz Reduces Sleep Onset Time by 53%

A wearable tES device delivering 0.75 Hz stimulation before sleep reduced sleep onset latency by 53% in insomnia sufferers. Validates eMedica’s frequency-based approach as an adjuvant for sleep and circadian rhythm disorders.

Prescribed Medication

Your doctor’s treatment plan — the primary therapy. Always continued and never replaced.

eMedica VCF Therapy

Restores cellular electrical health, amplifies medication effectiveness and immune response.

Evidence-Based Diet

Condition-specific nutrition creates the ideal internal environment for therapy to work.

Heart Rate & ECG

Continuous ECG waveform monitoring and real-time heart rate tracking via integrated electrodes. Patent Claim: ECG Sensor.

Blood Glucose (PPG)

Non-invasive blood glucose estimation via Photoplethysmogram (PPG) optical sensor. Continuous diabetic monitoring. Patent Claim: PPG Sensor, Glucometer.

SpO₂ & Oxygen

Peripheral capillary oxygen saturation (SpO₂) via pulse oximetry. Critical for respiratory and cardiac monitoring. Patent Claim: SpO₂ Sensor.

Blood Pressure

Continuous BP monitoring — systolic, diastolic and mean arterial pressure tracking for hypertension management. Patent Claim: BP Sensor, IBP Sensor.

HRV & Stress

Heart Rate Variability (HRV) and stress level monitoring — key indicators of autonomic nervous system health. Patent Claim: Fitness Tracker / HRV.

Sleep & Activity

Sleep duration and quality, steps, calories burnt, and cumulative distance walked for comprehensive daily health tracking. Patent Claim: Fitness Tracker.

Skin Temperature

Continuous skin surface temperature monitoring — fever detection, inflammation tracking, and thermal therapy feedback. Patent Claim: Temperature Sensor.

Real-Time Remote Alert

When any parameter breaches a threshold, the device automatically alerts your doctor, hospital, or caretaker via the cloud in real time. Patent Claim: Health Evaluation Unit.

BLOCKCHAIN HEALTH RECORDS

Your Health Data. Secured. Yours Forever.

The eMedica Wearable Band creates an immutable, encrypted personal health record on a distributed blockchain — giving you complete ownership of your health data while enabling seamless sharing with doctors and hospitals, all under your control.

eMedica is a non-invasive adjuvant therapy device. It is designed exclusively to support and complement prescribed medication and established medical care — not to replace it. eMedica does not claim to cure, diagnose, or treat any disease or health condition. All benefits described are adjuvant support outcomes observed in supervised clinical settings alongside standard medical treatment. Individual results may vary. Always consult a qualified, licensed healthcare professional before starting any therapy.

• India: Registered with CDSCO & FDA India
• Europe: CE Marked under applicable Medical Device Regulations
• Quality: ISO Certified • NABL Accredited • ROHS Compliant
• Patent: US Patent 12226183B2 (also filed: Japan, Eurasia, UAE, Saudi Arabia; 90+ countries pending)
• Other countries: Regulatory status varies by jurisdiction. Users must verify local compliance before use.

The hospitals and institutions listed on this website are independent clinical study and medical camp sites where observational data was gathered. They are not commercial partners of, affiliated with, or endorsing entities for Rohera Healthcare and Technology Pvt. Ltd. Patient counts and outcomes are from observational studies conducted at these institutions. These institutions have been verified as locations where clinical trials and medical camps were conducted.

Third-party peer-reviewed publications linked on this website are independent research by global scientists and are provided for scientific reference only. They are not eMedica-specific studies and do not specifically endorse the eMedica device. eMedica’s own publications are listed separately under the Publications section. All referenced research has been published in indexed international medical journals.

The eMedica Wearable Band is currently under development and has not yet received final regulatory approvals for commercial sale. Launch timelines, features, and specifications shown are indicative and subject to change without notice. No purchasing decision should be made solely based on features of an unreleased product. Register your interest to receive official launch announcements.

All content on this website is provided for informational and educational purposes only. It does not constitute medical advice, diagnosis, or a recommendation for any specific therapy. Rohera Healthcare and Technology Pvt. Ltd. makes no warranties regarding the accuracy or completeness of information provided. For personalised medical guidance, always consult a qualified healthcare provider. Translations provided by Google Translate are automated and may not be perfectly accurate for medical terminology.